tanzania times : Latest News and In-depth Analysis
Contact Us
Search

Sports

tanzania times : Latest News and In-depth Analysis
HomeSports
Sports

Mar 18, 2025

Optoma Introduces the Ultimate Display Management Solution

TAIPEI,March 18,2025-- The widely acclaimed Optoma Management Suite (OMS),an innovative display device management system highly praised by IT administrators,has undergone a comprehensive upgrade in 20

All News

Sports

Brook Gaming Introduces Wingman FGC 2: Breaking Limits, Redefining Control!

TAIPEI,Feb. 8,2025-- With the PlayStation 5 Pro taking the gaming world by storm,Taiwan\'s leading gaming peripheral brand,Brook Gaming,is back with a groundbreaking new product—Wingman FGC 2 Convert

Feb 10, 2025

Sports

CARsgen's First Enrolled Subject in the THANK-u Plus™ Platform-Based Allogeneic CAR-T Trial Achieves sCR at Week 4

SHANGHAI,Feb. 10,2025-- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK),a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors

Feb 10, 2025

The 9th Asian Winter Games takes place

HARBIN,China,Feb. 8,2025-- A report fromiQingdao: Video from IQingDao The opening ceremony of the 9th Asian Winter Games takes place in Harbin,Northeast China\'s Heilongjiang province,on Feb 7.

Feb 10, 2025

Global Times: Observing China's He Culture through the lens of Spring Festival

BEIJING,Feb. 6,2025-- TheQingcheng Palace complex at the Xiannongtan Temple,a gem along Beijing Central Axis,is the first ancient palace complex that was revitalized and unveiled after the Beijing Cen

Feb 7, 2025

Sports

TRILLER PUTS CREATORS FIRST AS IT UNLEASHES THE FUTURE OF TECH, MUSIC & CULTURE WITH THE LATEST VERSION OF ITS APP

Powered by next-generation technology and with data privacy front and center,Triller is redefining the creator economy with new ways for brands and creators to own their content,connect with their fa

Feb 7, 2025

Akeso Announces the Completion of Patient Enrollment in the Phase III Clinical Trial (HARMONi-6) Comparing Ivonescimab and Tislelizumab for First-Line Treatment of Sq-NSCLC

HONG KONG,Feb. 6,2025--Akeso,Inc. (9926.HK) ("Akeso" or the "Company")is excited to announce the completion of patient enrollment in the global Phase III clinical trial (HARMONi-6/

Feb 7, 2025

1 ... 67 68 69 70 71 72 73 ... 102